QualityDipStocks / Health Care · Pharmaceuticals
Rhythm Pharmaceuticals RYTM
Outside our quality screen, so we don’t track its dips. It’s 21% below its 52-week high.
Outside our quality screen, 6% under its Market Value. No fair value estimate for now: its free cash flow is negative.
Worth knowing
- Down 24% from its 52-week high while revenue grew 54%
From the data on this page, as of the last close. How we pick these
- Fair value est.
- n/a
- Market Value
- $99.70price −6%
- Off 52-wk high
- −21%
- Risk vs market
- Market-likebeta 1.04
5 bullish · 5 bearish See why
Repriced or dip?
Dip: business intact
The price is 21% below its 52-week high (Dec 11), but the business held up: revenue +37.6%, operating margin +23.2 pts, net cash (cash minus debt) −1.3% of market cap since the high.
Some numbers held up (revenue +37.6%, operating margin +23.2 pts, net cash (cash minus debt) −1.3% of market cap since the high), others slipped. The price is 21% below its 52-week high.
The price is 21% below its 52-week high, and the business changed too.
Within 10% of its 52-week high, so there is no dip to judge yet.
The evidence 7 numbers, high vs now
- Revenue, last 12 months$174M → $240M (+37.6%)held up
- Revenue growth rate+54.9% → +53.5% a year (−1.4 pts)about the same
- Operating margin−106.8% → −83.6% (+23.2 pts)held up
- Shares outstanding+3.4% (more shares, each owns less)about the same
- Net cash (cash minus debt)−1.3% of market cap since the highheld up
- Stock vs its sector (Health Care)stock −21%, sector median +17% since Dec 11changed
- Price fall vs business numbersprice −21%, revenue/EPS/FCF median +38% (shown, not scored)
Business numbers as reported at the high (12 months to Sep 30, 2025) vs the latest filing (12 months to Jun 30, 2026). Each measure is scored from −1 (business changed) to +1 (business intact) and weighted: revenue, earnings per share, free cash flow, operating margin, revenue growth rate, share count, net cash and the move vs its sector. 60 or more reads as a dip, 40 or less as a repricing. Analyst estimates are not in our data, so they are not used. How to read it
Data-based read, not advice.
Valuation
What we estimate it's worth, and how it ranks on value vs every stock we cover.
Fair value estimate
No estimate for RYTM: negative free cash flow. We’d rather show nothing than a made-up number.
Risk vs market
How risk vs market is measured
One year of daily returns (Oct 31 to Nov 2, 252 sessions). Beta = how much RYTM moved for each 1% move in the S&P 500 (SPY); 1.0 moves with the market. Volatility is the yearly standard deviation of daily returns. Past behavior, not a forecast.
Moves about in line with the market, and its own price swings are 3.6× the S&P 500’s.
- Beta vs S&P 500
- 1.04
- Volatility
- 46% vs 13% SPY
- Correlation SPY
- 0.29
- Correlation QQQ
- 0.21
How it ranks
Where RYTM stands vs every one of the 1,996 stocks we cover that has the number. Longer bar = better.
Top quarter on 1 of 3 measures
- Dividends + buybacks yield0% · cash paid out or used to retire shares, vs market capLowest 1%of 1,836
- Revenue growth, last 12 months+54% · vs the 12 months beforeTop 7%of 1,814
- Operating margin−84% · of sales kept as operating profitLowest 1%of 1,288
From SEC filings and our fair value estimate model. A ranking, not advice.
Valuation details
MV $99.70
Fundamentals
The business itself: sales, profits, cash and debt, from SEC filings.
Bull vs bear
Rule-based from the data on this page, strongest first. Not advice.
Top bullish points 5 of 5
GrowthSales grew 54% to $240M over the last 12 months vs the 12 months before (SEC filings).
ProfitabilityOperating margin widened to −101.2% in FY2025 from −238.1% in FY2023 (SEC filings).
GrowthSales compounded 100% a year from FY2022 to FY2025.
Balance sheetNet cash of $225M: cash and short-term investments exceed debt (Jun 30, 2026).
ValuationTrades 6.3% below its Market Value of $99.70, the average price paid since the Aug 4 filing.
Top bearish points 5 of 5
ValuationFree cash flow is negative (−$117M over the last 12 months), so there’s no cash-flow value under the price.
Balance sheetOperating income covers interest only -10.9× over the last 12 months.
ProfitabilityLost $210M over the last 12 months (net income, SEC filings).
ProfitabilityLoses money at the operating line: −84% operating margin over the last 12 months.
QualityDoesn’t pass our quality screen: no positive free cash flow; ROE under 12% and ROIC under 10%.
All fundamentals
Sales +54%
Valuation
- P/E
- n/aloss over the last 12 months
- Price / FCF
- n/anot reported in its SEC filings
- FCF yield
- n/anot reported in its SEC filings
- EV / EBITDA
- n/aD&A or debt not tagged in SEC data
- Price / sales
- 26.68×
- Price / book
- 62.15×
- Market cap
- $6.4Blisted
- Enterprise value
- $6.2B
Growth
- Revenue, 12 months
- $240M
- Sales growth, 12 months
- +53.5%vs the 12 months before
- Sales growth, 3 yrs
- +100.2%/yrfrom FY2022
- Diluted EPS, 12 months
- −$3.12
- EPS growth, last FY
- n/afewer than two years of diluted EPS
- Net income, 12 months
- −$210M
- Net income growth
- n/anot reported in its SEC filings
Profitability
- Gross margin
- 89.0%
- Operating margin
- −83.6%
- Net margin
- −87.6%
- FCF margin
- n/anot reported in its SEC filings
- Return on equity
- n/an/m: very small or negative equity
- Return on invested capital
- n/aoperating income, debt, equity or cash not tagged
Balance sheet
- Cash & short-term inv.
- $331M
- Total debt
- $106M
- Net cash
- $225M
- Debt / equity
- 1.03×
- Interest coverage
- -10.9×operating income / interest
Cash flow & returns
- Free cash flow, 12 months
- n/anot reported in its SEC filings
- FCF growth, 12 months
- n/anot reported in its SEC filings
- Dividend yield
- 0%
- Payout ratio
- n/anot reported in its SEC filings
- Buybacks, 12 months
- n/anot reported in its SEC filings
- Share count, 1 year
- +7.7%diluted shares vs a year ago
- Stock-based comp
- $87M
Trailing 12 months to Jun 30, 2026; balance sheet at Jun 30, 2026. From Rhythm Pharmaceuticals’s SEC filings. Sparklines show up to six fiscal years. n/a means we don’t hold that number, with the reason. How each is computed.
The business
FCF $-0.1B · Sales +47%
- Free cash flow, 12 months−$0.1B
- Free-cash-flow yield−2.0%
- Free-cash-flow margin−54%
- Gross margin89%
- Operating margin−68%
- Return on equity−117%
- Sales growth (latest quarter vs year-ago quarter)+47%
Chart & levels
Where the price is vs its key levels and trends.
Key levels
Every level vs today’s $93.44
- 52-wk lowlowest close, 1 year$75.82−18.9%
- PriceMon Nov 2 close$93.44you are here
- Market Valueavg paid since Aug 4$99.70+6.7%
- 52-wk highhighest close, 1 year$117.62+25.9%
Momentum & 52-week range
RSI 53 · 5 days +4.4%
Signals
Reversal signal setups, the public ledger and the next earnings date.
Setup & signals
No setup armed
No setup armed, so there’s no trigger or stop to track yet. Reversal signal rules only run on companies that pass our quality screen.
Next report
Nov 3
- DateTue Nov 3, before the open
- Consensus EPS($0.68)
- Year-ago EPS($0.82)
- QuarterSep/2026
From Nasdaq’s earnings calendar. A report resets Market Value.
RYTM is outside our quality screen
One text when a published rule fires on one of the 332 quality companies we track: the ticker, the price, the stop and a link to the numbers. Nothing else.
Voices & buzz
Who is talking about it, and how it compares with peers.
Who’s talking about it
Notable investors, executives, analysts and public figures on Rhythm Pharmaceuticals in the last 48 hours. Headlines as published, each linked. Their words, not ours.
No notable mentions in the last 48 hours. Checked Nov 3, 1:01 PM ET.
Compare with peers
Closest in size in Pharmaceuticals
Information only, not investment advice. Fair value estimates and talking points are rule-based model output from public data and can be wrong; stop levels are reference points, not orders. How every number is computed.